Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $165

Benzinga Newsdesk www.benzinga.com Positive 88.7%

Neg 0% Neu 0% Pos 88.7%

Wedbush analyst Robert Driscoll maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $147 to $165.